A Phase 3 interventional study of BFF MDI 320/9.6 μg and BFF MDI 160/9.6 μg in Asthma, sponsored by AstraZeneca. Completed at 142 sites in 7 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 20th largest by enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2022, is one of 51 in phase 3, and was the 102nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 645 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 55th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 121 in phase 3, and was the 289th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
This is a Phase III randomized, double-blind, active comparison, parallel group, multicenter study comparing BFF MDI 320/9.6 μg to BD MDI 320 µg and open-label Symbicort TBH 320/9 μg in adult and adolescent participants who have asthma which remains inadequately controlled (ACQ-7 total score ≥ 1.5) despite treatment with medium dose ICS or ICS/LABA. Budesonide and Formoterol Fumarate MDI 160/9.6 μg is included in this study to evaluate dose response by comparing to BFF MDI 320/9.6 μg. All doses represent the sum of 2 actuations. All study interventions will be administered BID for 24 weeks.
This study will be conducted at approximately 125 sites worldwide and will randomize approximately 630 adult and adolescent participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
Drug: BFF MDI 320/9.6 μg
Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
Drug: BFF MDI 160/9.6 μg
Budesonide MDI (BD MDI), 320 μg
Drug: BD MDI 320 μg
Open-Label Comparator Symbicort Turbuhaler 320/9 μg
Drug: Open-label Symbicort TBH 320/9 μg
Drug pages: Budesonide · Formoterol
Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
Also known as: BFF
Drug pages: Budesonide · Formoterol
Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
Also known as: BFF
Budesonide MDI (BD MDI), 320 μg
Also known as: BD
Open-label Symbicort Turbuhaler 320/9 μg
Also known as: Symbicort TBH
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 24
Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24. FEV1 AUC0-3 is calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time to report the result in liters. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: At Week 24
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24
Change from baseline in morning pre-dose trough FEV1 at Week 24. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: At 24 Weeks
Onset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 1
Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: On Day 1
Change From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 24 Weeks
Change from baseline in the mean number of puffs of rescue medication use (puffs/day) over 24 Weeks. Baseline is the average during the last 7 days before randomization. Over 24 weeks is the average from randomization up to week 24. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: Over 24 Weeks
Percentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 24
Percentage of responders in ACQ-7 at Week 24, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: At Week 24
Percentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 24
Percentage of responders in ACQ-5 at Week 24, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: At Week 24
Percentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) (≥ 0.5 Increase Equals Response) at Week 24
Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) at Week 24, where responders are defined as participants with a ≥0.5 increase in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: At Week 24
Rate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks)
As requested by a Health Authority, data from VATHOS and LITHOS (NCT05755906), two studies originally designed to assess lung function, were pooled to analyze the annualized rate of severe asthma exacerbations. This analysis was prespecified, uses data up to 12 weeks for LITHOS and 24 weeks for VATHOS, and was incorporated into the multiple testing procedure. An exacerbation is considered severe if it results in at least one of the following: a course of systemic corticosteroids (SCS) for ≥3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma requiring treatment with SCS, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events except for initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is used.
Time frame: 24 Weeks
Rate of Severe Asthma Exacerbation During the Treatment Period (up to 24 Weeks)
Annualized rate of severe asthma exacerbation during the treatment period (up to 24 Weeks). An asthma exacerbation will be considered severe if it results in at least one of the following: a course of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma that required treatment with systemic corticosteroids, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
Time frame: 24 Weeks
Participants who have asthma which remains inadequately controlled (ACQ-7 total score ≥ 1.5) despite treatment with medium dose ICS or ICS/LABA were recruited at 147 sites across 7 countries. Participants were randomized in a 1:2:2:2 scheme to BFF MDI 160/9.6 μg, BFF MDI 320/9.6 μg, BD MDI 320 μg, or open-label Symbicort. Randomization was stratified by baseline asthma treatment and age. The treatment period was 24 weeks in duration with up to 8 in-clinic visits during screening and treatment.
| Milestone | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g |
|---|---|---|---|---|
| Started | 88 | 163 | 168 | 162 |
| Completed | 81 | 150 | 155 | 151 |
| Not completed | 7 | 13 | 13 | 11 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 0 |
| Withdrew: Physician decision | 3 | 3 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Development of withdrawal criteria | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 5 | 4 |
| Withdrew: Various reasons | 2 | 5 | 3 | 4 |
| Withdrew: Failure to meet randomization criteria | 0 | 1 | 0 | 1 |
Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24. FEV1 AUC0-3 is calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time to report the result in liters. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Liter | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 24 | 0.276 ± 0.0300 | 0.240 ± 0.0219 | 0.067 ± 0.0216 | 0.240 ± 0.0220 |
Change from baseline in morning pre-dose trough FEV1 at Week 24. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Liter | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 | 0.125 ± 0.0293 | 0.099 ± 0.0215 | 0.038 ± 0.0211 | 0.131 ± 0.0216 |
Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Liter | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Onset of Action on Day 1: Absolute Change in FEV1 at 5 Minutes on Day 1 | 0.236 ± 0.0167 | 0.184 ± 0.0122 | 0.041 ± 0.0121 | 0.161 ± 0.0123 |
Change from baseline in the mean number of puffs of rescue medication use (puffs/day) over 24 Weeks. Baseline is the average during the last 7 days before randomization. Over 24 weeks is the average from randomization up to week 24. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Puffs/Day | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Change From Baseline in the Mean Number of Puffs of Rescue Medication Use (Puffs/Day) Over 24 Weeks | -0.350 ± 0.1061 | -0.481 ± 0.0781 | -0.213 ± 0.0764 | -0.443 ± 0.0791 |
Percentage of responders in ACQ-7 at Week 24, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Percentage of participants | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Percentage of Responders in ACQ-7 (≥ 0.5 Decrease Equals Response) at Week 24 | 70.7 | 68.4 | 62.7 | 71.4 |
Percentage of responders in ACQ-5 at Week 24, where responders are defined as participants with a ≥0.5 decrease in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Percentage of participants | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Percentage of Responders in ACQ-5 (≥ 0.5 Decrease Equals Response) at Week 24 | 75.6 | 71.6 | 65.8 | 68.8 |
Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) at Week 24, where responders are defined as participants with a ≥0.5 increase in total score from baseline. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Percentage of participants | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Percentage of Responders in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) (≥ 0.5 Increase Equals Response) at Week 24 | 53.2 | 57.7 | 47.1 | 50.3 |
As requested by a Health Authority, data from VATHOS and LITHOS (NCT05755906), two studies originally designed to assess lung function, were pooled to analyze the annualized rate of severe asthma exacerbations. This analysis was prespecified, uses data up to 12 weeks for LITHOS and 24 weeks for VATHOS, and was incorporated into the multiple testing procedure. An exacerbation is considered severe if it results in at least one of the following: a course of systemic corticosteroids (SCS) for ≥3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma requiring treatment with SCS, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events except for initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is used.
| Exacerbations/year | BFF MDI 160/9.6 μg or 320/9.6 μg | BD MDI 160 μg or 320 μg |
|---|---|---|
| Rate of Severe Asthma Exacerbation (Pooled LITHOS and VATHOS Data) During the Treatment Period (up to 24 Weeks) | 0.35 ± 0.05 | 0.42 ± 0.07 |
Annualized rate of severe asthma exacerbation during the treatment period (up to 24 Weeks). An asthma exacerbation will be considered severe if it results in at least one of the following: a course of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening, an ER or urgent care visit due to asthma that required treatment with systemic corticosteroids, an in-patient hospitalization due to asthma, or death related to asthma. Treatment policy is implemented to handle all intercurrent events with the exception of initiation of new asthma therapy or administration of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of randomised study intervention, for which the composite strategy is implemented.
| Exacerbations/year | BFF MDI 160/9.6 μg | BFF MDI 320/9.6 μg | BD MDI 320 μg | Symbicort TBH 320/9 μg |
|---|---|---|---|---|
| Rate of Severe Asthma Exacerbation During the Treatment Period (up to 24 Weeks) | 0.26 ± 0.08 | 0.36 ± 0.07 | 0.35 ± 0.07 | 0.41 ± 0.07 |
Collected over From the date of first dose of IP up to and including 1 day following the date of last IP dose, up to 24 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BFF MDI 160/9.6 g | 0/88 (0%) | 3/88 (3.4%) | 31/88 (35.2%) |
| BFF MDI 320/9.6 g | 0/163 (0%) | 3/163 (1.8%) | 45/163 (27.6%) |
| BD MDI 320 g | 0/168 (0%) | 1/168 (0.6%) | 40/168 (23.8%) |
| Symbicort TBH 320/9 g | 0/162 (0%) | 7/162 (4.3%) | 39/162 (24.1%) |
| Event | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g |
|---|---|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 1/88 | 0/163 | 0/168 | 0/162 |
| Gastric ulcerGastrointestinal disorders | 1/88 | 0/163 | 0/168 | 0/162 |
| Inguinal herniaGastrointestinal disorders | 1/88 | 0/163 | 0/168 | 0/162 |
| Cholecystitis acuteHepatobiliary disorders | 0/88 | 0/163 | 0/168 | 1/162 |
| DiverticulitisInfections and infestations | 0/88 | 0/163 | 0/168 | 1/162 |
| Localised infectionInfections and infestations | 0/88 | 0/163 | 0/168 | 1/162 |
| Decreased appetiteMetabolism and nutrition disorders | 0/88 | 0/163 | 0/168 | 1/162 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/88 | 1/163 | 0/168 | 1/162 |
| Large intestine polypGastrointestinal disorders | 0/88 | 0/163 | 0/168 | 1/162 |
| AstheniaGeneral disorders | 0/88 | 0/163 | 0/168 | 1/162 |
| Event | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/88 | 15/163 | 15/168 | 13/162 |
| Covid-19Infections and infestations | 3/88 | 15/163 | 8/168 | 11/162 |
| Upper respiratory tract infectionInfections and infestations | 3/88 | 8/163 | 12/168 | 9/162 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/88 | 1/163 | 1/168 | 2/162 |
| HypertensionVascular disorders | 3/88 | 1/163 | 3/168 | 1/162 |
| Viral upper respiratory tract infectionInfections and infestations | 1/88 | 3/163 | 3/168 | 5/162 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/88 | 4/163 | 0/168 | 1/162 |
| Bronchitis bacterialInfections and infestations | 2/88 | 2/163 | 2/168 | 2/162 |
| GoutMetabolism and nutrition disorders | 2/88 | 1/163 | 0/168 | 0/162 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/88 | 3/163 | 1/168 | 0/162 |
The Efficacy Set is defined as all participants who are randomized to study intervention and receive any amount of randomized study intervention. It excludes 6 participants who were randomized before or concurrently in another study.
| Age, Continuous(Years) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Mean | 49.4 ± 17.2 | 49.7 ± 15.8 | 49.0 ± 15.2 | 51.3 ± 15.3 | 49.9 ± 15.7 |
| Sex: Female, Male(Participants) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Female | 48 | 101 | 108 | 101 | 358 |
| Male | 39 | 61 | 58 | 59 | 217 |
| Race/Ethnicity, Customized(Participants) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Black or African American | 9 | 16 | 17 | 24 | 66 |
| Asian | 9 | 22 | 18 | 19 | 68 |
| White | 64 | 119 | 122 | 112 | 417 |
| Other | 5 | 5 | 9 | 5 | 24 |
| Region of Enrollment(Participants) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Global — Canada | 6 | 13 | 10 | 8 | 37 |
| Global — Germany | 27 | 33 | 39 | 30 | 129 |
| Global — Italy | 4 | 4 | 1 | 6 | 15 |
| Global — Japan | 4 | 12 | 8 | 9 | 33 |
| Global — Spain | 3 | 6 | 7 | 6 | 22 |
| Global — United States | 40 | 88 | 97 | 92 | 317 |
| Global — Vietnam | 3 | 6 | 4 | 9 | 22 |
| Prior asthma medication(Participants) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| ICS | 11 | 17 | 20 | 19 | 67 |
| ICS/LABA | 76 | 145 | 145 | 141 | 507 |
| ICS/LAMA/LABA | 0 | 0 | 1 | 0 | 1 |
| Baseline reversibility (%)(Percentage) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Mean | 18.5 ± 11.3 | 17.5 ± 12.8 | 19.9 ± 11.0 | 20.0 ± 15.9 | 19.0 ± 13.1 |
| Baseline pre-bronchodilator FEV1 (L)(Liter) | BFF MDI 160/9.6 g | BFF MDI 320/9.6 g | BD MDI 320 g | Symbicort TBH 320/9 g | Total |
|---|---|---|---|---|---|
| Mean | 2.315 ± 0.666 | 2.163 ± 0.666 | 2.132 ± 0.561 | 2.103 ± 0.589 | 2.160 ± 0.618 |
Showing the first 100 of 142 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2022 to primary completion in Feb 2025, 37 months.
Results were first posted in Jan 2026, 11 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 37 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol